Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication

A phase Ib/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients.

(2020) George A. Fisher et al.   JOURNAL OF CLINICAL ONCOLOGY

Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study

(2020) Eugene Suh et al.   LANCET ONCOLOGY

The anti-disialoganglioside (GD2) antibody dinutuximab (D) for second-line treatment (2LT) of patients (pts) with relapsed/refractory small cell lung cancer (RR SCLC): Results from part II of the open-label, randomized, phase II/III distinct study.

(2020) Martin Edelman et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of antidisialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma (AOST1421): A report from the Children’s Oncology Group.

(2020) Pooja Hingorani et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

(2020) Charles M. Rudin et al.   JOURNAL OF CLINICAL ONCOLOGY

Harnessing natural killer immunity in metastatic small cell lung cancer

(2020) Sarah A. Best et al.   Journal of Thoracic Oncology

Tuning the Antigen Density Requirement for CAR T-cell Activity

(2020) Robbie G. Majzner et al.   Cancer Discovery

Targeted glycan degradation potentiates the anticancer immune response in vivo

(2020) Melissa A. Gray et al.   Nature Chemical Biology

Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy

(2019) Jun Wang et al.   NATURE MEDICINE

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers

(2019) Branimir I. Sikic et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells

(2019) Hong-Wei Wu et al.   CLINICAL CANCER RESEARCH

CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy

(2019) Amira A. Barkal et al.   NATURE

Improving the efficacy of osteosarcoma therapy: combining drugs that turn cancer cell ‘don't eat me’ signals off and ‘eat me’ signals on

(2019) Suchismita Mohanty et al.   Molecular Oncology

c-Jun overexpression in CAR T cells induces exhaustion resistance

(2019) Rachel C. Lynn et al.   NATURE

Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T Cell Receptors in High-riskMYCN-not-amplified Human Neuroblastoma

(2018) Jun S. Wei et al.   CLINICAL CANCER RESEARCH

Magnetic Resonance Imaging of Tumor-Associated Macrophages: Clinical Translation

(2018) Maryam Aghighi et al.   CLINICAL CANCER RESEARCH

Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas

(2018) Christopher W. Mount et al.   NATURE MEDICINE

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial

(2018) Ruth Ladenstein et al.   LANCET ONCOLOGY

Temporal patterns in the risk of chronic health conditions in survivors of childhood cancer diagnosed 1970–99: a report from the Childhood Cancer Survivor Study cohort

(2018) Todd M Gibson et al.   LANCET ONCOLOGY

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

(2018) Ranjana Advani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice

(2017) Megan Lo et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors

(2017) Sharareh Gholamin et al.   Science Translational Medicine

Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials

(2016) Lucas Moreno et al.   PEDIATRIC BLOOD & CANCER

Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults

(2016) Konstantin Dobrenkov et al.   PEDIATRIC BLOOD & CANCER

Durable antitumor responses to CD47 blockade require adaptive immune stimulation

(2016) Jonathan T. Sockolosky et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas

(2016) A. H. Long et al.   Cancer Immunology Research

Comprehensive genomic profiles of small cell lung cancer

(2015) Julie George et al.   NATURE

Anti-proliferative and pro-apoptotic activity of GD2 ganglioside-specific monoclonal antibody 3F8 in human melanoma cells

(2015) Chun-Yen Tsao et al.   OncoImmunology

Ganglioside GD2 in reception and transduction of cell death signal in tumor cells

(2014) Igor I Doronin et al.   BMC CANCER

Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma

(2014) Ami V. Desai et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma

(2013) Michael Roth et al.   CANCER

Engineered SIRP  Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies

(2013) K. Weiskopf et al.   SCIENCE

Development of an Fc-Enhanced Anti-B7-H3 Monoclonal Antibody with Potent Antitumor Activity

(2012) D. Loo et al.   CLINICAL CANCER RESEARCH

Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis

(2012) Venkata Lokesh Battula et al.   JOURNAL OF CLINICAL INVESTIGATION

Clinical Significance of Tumor-Associated Inflammatory Cells in Metastatic Neuroblastoma

(2012) Shahab Asgharzadeh et al.   JOURNAL OF CLINICAL ONCOLOGY

Murine Anti-GD2 Monoclonal Antibody 3F8 Combined With Granulocyte-Macrophage Colony-Stimulating Factor and 13-Cis-Retinoic Acid in High-Risk Patients With Stage 4 Neuroblastoma in First Remission

(2012) Nai-Kong V. Cheung et al.   JOURNAL OF CLINICAL ONCOLOGY

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

(2012) S. B. Willingham et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma

(2010) Mark P. Chao et al.   CELL

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

(2010) Alice L. Yu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-GD2 with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia

(2010) Linda S. Sorkin et al.   PAIN

CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis

(2009) Siddhartha Jaiswal et al.   CELL

Vα24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages

(2009) Liping Song et al.   JOURNAL OF CLINICAL INVESTIGATION

Late effects in survivors of tandem peripheral blood stem cell transplant for high-risk neuroblastoma

(2008) Wendy L. Hobbie et al.   PEDIATRIC BLOOD & CANCER